Switching From Allergy Shots to Sublingual Drops Without Restarting Your Desensitization

At-home sublingual immunotherapy can be an alternative to allergy shots without necessarily losing the tolerance already built through treatment. Shots and sublingual drops work through the same desensitization process, so a change from one to the other need not mean starting over. The transition still needs a clinician-directed plan, because shared biology does not make injection and drop doses interchangeable.

Why allergy shots and sublingual drops are two routes to the same destination

Allergy shots and sublingual drops both expose the immune system to controlled amounts of allergen, gradually building its ability to tolerate what it previously treated as a threat. Subcutaneous immunotherapy, or SCIT, delivers that exposure through injections. Sublingual immunotherapy, or SLIT, delivers it under the tongue. Both aim to change the allergic response rather than simply quiet symptoms while a medicine is being taken.

What connects those two routes inside the body? Dr. Adrian Morris’s overview of desensitization explains that both change the balance of T-helper cells, moving the immune response away from an IgE-driven allergic pathway and toward tolerance. That is the central biological link between them. Repeated exposure is intended to change how the immune system responds to the treated allergens over time.

Morris’s overview describes allergen-specific IgE falling over long-term SCIT, while reductions with SLIT are inconsistent or minimal. That distinction keeps the comparison honest. The argument for switching rests on the shared aim of shots and drops: durable immune tolerance. Both are meant to keep helping after a patient stops treatment.

What "immunological progress" actually means and why it doesn't vanish when the delivery route changes

The tolerance built through immunotherapy is a change in immune behavior throughout the body, extending beyond the injection site or the tissue under the tongue. This systemic effect is why a route change need not erase the work already done.

After repeated allergen exposure, treatment moves from building tolerance toward sustaining it. Missing a dose now and then need not restart that process, though keeping to the schedule helps treatment work better. Because tolerance can last through gaps in dosing, there is reason to think a planned switch can keep that progress, too.

How certain is that conclusion for someone changing treatments? No large randomized trial has directly studied mid-course SCIT-to-SLIT switching. The reassurance rests on the shared mechanism and clinician practice. That distinction deserves to stay in view. Biological continuity is a reason for confidence, but it is not a guarantee of a particular result or remaining treatment length.

The practical implication is narrower than “nothing changes.” Earlier treatment can still count even when a change in how it is given calls for a different dosing plan. Starting drops with an adjusted schedule does not, by itself, mean the immune system has forgotten what it learned during shots.

What a mid-course switch actually involves in practice

A mid-course switch begins with a reassessment of the patient’s current sensitization profile and prior treatment. The clinician uses that information to build the SLIT formulation and determine its dosing plan. Treatment still gives the patient controlled exposure to the allergens being treated, with a formulation that fits the patient’s needs now.

The most visible changes are format, location, and frequency. Instead of attending a clinic for injections, the patient takes prescribed drops under the tongue, typically in a daily routine at home. That changes the work of staying on treatment. Travel and appointment time give way to the responsibility of following the home dosing schedule consistently.

SLIT usually starts with a build-up phase in which the concentration increases, typically over several months, then moves to a maintenance phase that lasts several years. A patient moving from SCIT may enter that sequence at a point calibrated to existing tolerance. The dose is still an individual clinical decision. Previous shot treatment does not establish that every patient can bypass build-up or begin at the same concentration.

Custom drops can also combine treatment for multiple allergens in one daily dose. For someone moving from single-allergen SCIT, that may broaden what the plan addresses. Shots can treat multiple allergens as well. The distinction is therefore not exclusive access to multi-allergen treatment, but the ability to deliver a personalized combination at home without the recurring clinic visits that injections require.

Why patients switch mid-course and why the timing rarely disqualifies them

The most common reasons for switching are logistical. Weekly clinic visits can become difficult after a move, a change in work hours, or a growing conflict with other commitments. Needle aversion can add another obstacle. Travel and waiting also accumulate over a long course, even when each appointment seems manageable on its own.

None of those difficulties establishes immunological failure. A treatment can be working while its delivery schedule becomes unsustainable. That is why a mid-course change need not be framed as impatience or giving up. A different route’s ability to make continued treatment more realistic should guide the timing of a switch.

Adherence is central to that decision because the benefit depends on sustained allergen exposure. SLIT adherence is described as substantially higher than SCIT adherence, with less travel and needle anxiety removing common barriers. Home treatment still requires commitment, however. Convenience helps only when it becomes a routine the patient can maintain.

Asthma can make the decision more clinically complex. Poorly controlled asthma can increase the risk of adverse reactions to injections, and clinicians may postpone or suspend SCIT during flares. Désirée Larenas-Linnemann, MD, of Hospital Médica Sur discussed SLIT’s more favorable safety profile at the 2026 American Academy of Allergy, Asthma & Immunology annual meeting. That comparison makes asthma control part of the clinician’s assessment of whether, when, and how another route fits.

How long the full desensitization course takes and why completing it matters regardless of which route a patient uses

Durable tolerance requires sustained treatment, whether the allergen is delivered by injection or under the tongue. The evidence-supported commitment is at least three years of consistent immunotherapy. A switch may make the remaining course easier to complete while preserving previous progress.

Consider a patient who has completed one year of shots. During that year of injections, the patient has been moving along the desensitization pathway. A change to drops need not mean starting a fresh three-year clock. At the same time, the lack of a dedicated switching trial means the remaining course cannot be calculated by simple subtraction for every patient. The treatment plan needs to reflect where that individual is now.

Larenas-Linnemann described clinical trials in which patients who completed three years of high-dose grass pollen sublingual tablets had improved symptoms for at least two additional years after they stopped. The benefit outlasted the dosing. That finding concerns grass pollen tablets, however, and should not be presented as a direct result for every custom drop formulation or every mid-course switch.

The broader aim is disease modification. Immunotherapy may lower the risk of developing asthma in patients who currently have allergic rhinitis alone. The reason to finish is not loyalty to shots or drops, but the prospect of changing the longer-term course of allergic disease.

What updated clinical guidance says about SLIT's place alongside — and not just beneath — injection therapy

Larenas-Linnemann presented “What Should You Know About SLIT in 2026?” at the AAAAI annual meeting in Philadelphia. Her session addressed SLIT’s evidence base and its place in treating allergic rhinitis and asthma. The discussion showed how the sublingual route fits into the wider effort to treat the immune dysfunction behind allergic disease.

Larenas-Linnemann also noted that strong published evidence on sublingual immunotherapy has been available since 2006. That gives the route a two-decade evidence base rather than the standing of a new workaround for people who dislike needles. Choosing SLIT can be a medically defensible treatment decision.

Updated practice parameters for allergen immunotherapy are in development and are expected to expand guidance on sublingual treatment. They are not yet completed guidance. Their anticipated direction suggests clearer recommendations for incorporating SLIT into routine allergy care, while leaving clinicians responsible for matching treatment to the patient.

Recognition of the route still needs to be separated from evidence for a particular formulation. A trial of sublingual tablets does not establish every claim about custom drops, just as a conference presentation does not prove a specific switching schedule. Those boundaries help a patient distinguish a well-supported treatment approach from an overly broad promise about exactly how their transition will unfold.

Can I stop allergy shots and switch to a personalized drop plan at home?

The next step is an assessment led by a clinician, before the patient stops shots or chooses a drop dose on their own. Current, accurate allergy testing anchors that assessment because sensitivities can evolve during years of treatment. The formula depends on the profile it addresses. The patient’s past shots help inform the plan, while testing shows which allergens it needs to cover now.

At-home finger-prick IgE blood-spot testing can identify sensitization to environmental allergens, including pollens, dust mites, mold, and pet dander. Telehealth care can arrange and interpret that testing without an in-office visit. The results need clinical interpretation. They become the basis for a personalized formula together with the patient’s medical history, rather than serving as a dosing instruction by themselves.

Once the assessment is complete, a personalized SLIT formulation can be compounded and delivered to the patient’s door. Virtual consultations, home testing, and home dosing address many of the same obstacles that make weekly injection visits difficult. This is the practical appeal for shot switchers. A sustained three-to-five year commitment may become more realistic when treatment no longer depends on proximity to a clinic or repeated time away from work.

Cost remains part of that fit. Telehealth treatment plans can be FSA/HSA eligible, allowing eligible expenses to be paid through existing health spending accounts. That does not establish that drops will cost less for every patient. A useful comparison includes the ongoing cost of shots and copays, the cost of the drop plan, and the time required to keep attending appointments.

Does the formulation address the current allergen profile, does the starting schedule account for prior treatment, and is the remaining commitment realistic? A plan for switching needs to address all of those questions together. It gives the patient a workable way to continue desensitization, without confusing a new daily routine with an immune system starting from zero.